Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Myelodysplastic Syndrome
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(129)
News
Trials
Search handles
@AlkaliDr
@Anand_88_Patel
@BenWestphalen
@CLachowiez
@DavidSteensma
@DrMarcosdelima
@Dr_AmerZeidan
@Dr_R_Kurzrock
@PLMcCarthyMD
@Prasshmehta
@SCTNB
@TaylorJ_MD
@Transplant_Doc
@VivekSubbiah
@ZaidAR_MD
@albertomussetti
@davidhenrymd
@diegoah66
@doctorpemm
@michaelwangmd
@mtmdphd
@n_gangat
@smbenlazar
@syed_abutalibmd
@tomleblancMD
@weldeiry
Search handles
@AlkaliDr
@Anand_88_Patel
@BenWestphalen
@CLachowiez
@DavidSteensma
@DrMarcosdelima
@Dr_AmerZeidan
@Dr_R_Kurzrock
@PLMcCarthyMD
@Prasshmehta
@SCTNB
@TaylorJ_MD
@Transplant_Doc
@VivekSubbiah
@ZaidAR_MD
@albertomussetti
@davidhenrymd
@diegoah66
@doctorpemm
@michaelwangmd
@mtmdphd
@n_gangat
@smbenlazar
@syed_abutalibmd
@tomleblancMD
@weldeiry
Filter by
Latest
9ms
this Phase III wasn't limited to TP53, it was HMA-naive higher-risk MDS (@Anand_88_Patel)
9 months ago
P3 data
|
TP53 (Tumor protein P53)
9ms
First JAMA article was published last year - Myelodysplastic Syndromes https://t.co/mqqEDogZRP with @MikkaelSekeres @SylvesterCancer #MDSsm #leusm (@TaylorJ_MD)
9 months ago
9ms
❓ What's the latest in lower-risk myelodysplastic syndrome (LR-MDS) management? Join as Dr. @Ramikomrokji summarizes the latest data. #CME #MedEd #MedTwitter 🖥️ Take our activity here: https://t.co/yLAdWHt2fa (@MedscapeCME)
9 months ago
9ms
Dr. Rami Komrokji from Moffitt Cancer Center discussing the latest news on myelodysplastic syndrome. @MoffittNews @ASH_hematology @Ramikomrokji @ACPIMPhysicians @FAUMedSchool @mecmededucation @SylvesterCancer @MCIStrong @TGHCares @FLASCO_ORG (@EdgardoSantosMD)
9 months ago
9ms
❓ What's the latest in lower-risk myelodysplastic syndrome (LR-MDS) management? Join as Dr. @Ramikomrokji summarizes the latest data. #CME #MedEd #MedTwitter 🖥️ Take our activity here: https://t.co/wf0tDOMBDC (@MedscapeCME)
9 months ago
10ms
CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH MULTIPLE MYELOMA WHO DEVELOPED THERAPY-RELATED ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME FOLLOWING AUTOLOGOUS CELL TRANSPLANTATION https://t.co/ZuGML7u2RJ @Fevzi_F_Yalniz @DQBMD @MDAndersonNews #bmtsm #leusm #mmsm (@Transplant_Doc)
10 months ago
Clinical
10ms
📣 #ESHMDS2024 ABSTRACT SUBMISSION IS OPEN! Submit yours now ➡ https://t.co/srVk8TI3Y1 9th Translational Research Conference: MYELODYSPLASTIC SYNDROMES Join us on April 12-14, 2024 in Budapest, Hungary 🇭🇺 Chairs: @FenauxP, @GoetzeKatharina, @MikkaelSekeres #ESHCONFERENCES #MDSsm (@ESHaematology)
10 months ago
10ms
❓ What's the latest in lower-risk myelodysplastic syndrome (LR-MDS) management? Join as Dr. @Ramikomrokji summarizes the latest data. #CME #MedEd #MedTwitter 🖥️ Take our activity here: https://t.co/2TSqQEyZJw (@MedscapeCME)
10 months ago
10ms
❓ What's the latest in lower-risk myelodysplastic syndrome (LR-MDS) management? Join as Dr. @Ramikomrokji summarizes the latest data. #CME 🖥️ Take our activity here: https://t.co/Cg1L9lQh8g (@Medscape)
10 months ago
10ms
❓ What's the latest in lower-risk myelodysplastic syndrome (LR-MDS) management? Join as Dr. @Ramikomrokji summarizes the latest data. #CME #MedEd #MedTwitter 🖥️ Take our activity here: https://t.co/gOItwWZ326 (@MedscapeCME)
10 months ago
10ms
❓ What's the latest in lower-risk myelodysplastic syndrome (LR-MDS) management? Join as Dr. @Ramikomrokji summarizes the latest data. #CME #MedEd #MedTwitter 🖥️ Take our activity here: https://t.co/9S45R20cz9 (@MedscapeCME)
10 months ago
10ms
How do you distinguish between a diagnosis of MDS and AML? MDS specialist Sanikommu Srinivasa @srsanikommu from Levine Cancer Center explains! For more MDS resources visit https://t.co/3iKx37vH90. #HealthTreeMDS #MDS #mdssm #myelodysplasticsyndromes #hematology #bloodsyndro… (@HealthTreeMDS)
10 months ago
10ms
❓ What's the latest in lower-risk myelodysplastic syndrome (LR-MDS) management? Join as Dr. @Ramikomrokji summarizes the latest data. #CME #MedEd #MedTwitter 🖥️ Take our activity here: https://t.co/wbADPZU8iJ (@MedscapeCME)
10 months ago
10ms
❓ What's the latest in lower-risk myelodysplastic syndrome (LR-MDS) management? Join as Dr. @Ramikomrokji summarizes the latest data. 🖥️ Take our activity here: https://t.co/kxLN68SjQu (@MedscapeOnc)
10 months ago
10ms
Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS) @Dr_AmerZeidan #MDS https://t.co/epw4pifeHS (@smbenlazar)
10 months ago
Clinical
10ms
WATCH: @Ramikomrokji, of @MoffittNews, discusses ongoing clinical trials in patients with higher- and lower-risk myelodysplastic syndromes. #hematology #oncology https://t.co/Akwq7ct1cy (@OncLive)
10 months ago
Clinical
10ms
Einige Personen mit myelodysplastischem Syndrom profitieren von #Imetelstat. Im Vergleich zu Placebo konnte die Zeit ohne Transfusionen signifikant verlängert werden – bei 17,8% der Verumgruppe sogar bis zu einem Jahr oder länger. #EHA23 #Krebs https://t.co/HDjus7dfNG (Reg.) (@SpringerMedizin)
10 months ago
Clinical
|
imetelstat (GRN163L)
10ms
🙌 #ESHMDS2024 CALL FOR ABSTRACTS! Deadline: January 15th, 2024 ➡ https://t.co/srVk8TI3Y1 🗓️ April 12-14, 2024 📍 Budapest, Hungary 🇭🇺 9th Translational Research Conference: MYELODYSPLASTIC SYNDROMES Chairs: @FenauxP, @GoetzeKatharina, @MikkaelSekeres #ESHCONFERENCES #MDSsm (@ESHaematology)
10 months ago
10ms
What is transfusion and how often would a patient get one? MDS specialist Sanikommu Srinivasa @srsanikommu from Levine Cancer Center explains! For more MDS resources visit https://t.co/3iKx37vH90. #HealthTreeMDS #MDS #mdssm #myelodysplasticsyndromes #hematology #bloodsyndro… (@HealthTreeMDS)
10 months ago
Clinical
10ms
Leukemia, Myelodysplastic Syndromes, and Myeloproliferative Neoplasms https://t.co/VSUATV9JQ6 via @MedscapeCME (@MSourri)
10 months ago
10ms
Amer Methqal Zeidan, MBBS, MHS, on Myelodysplastic Syndromes: New Data From the IMerge Study of Imetelstat https://t.co/XHF9l9wlN0 #MDS #hematology @Dr_AmerZeidan @Yale @YaleCancer (@ASCOPost)
10 months ago
imetelstat (GRN163L)
11ms
I don’t know what 1202 is. What is it? We were told that there are 500 MDS patients with NGS. Using those 500. (@Dr_R_Kurzrock)
11 months ago
Clinical • Next-generation sequencing
11ms
WATCH: @Ramikomrokji, of @MoffittNews, introduces @sanamloghavi, of @MDAndersonNews, in a discussion on the typical patient presentation and diagnostic process in MDS, which was recently renamed as ‘myelodysplastic neoplasms’ in 2022. #oncology #hematology https://t.co/91mUJRIuZo (@OncLive)
11 months ago
Clinical
11ms
At #EHA2023, we are also presenting novel research on impairment in RBC metabolism and the role of pyruvate kinase activation in #MyelodysplasticSyndromes (#MDS). #AgiosMedical (@AgiosMedical)
11 months ago
11ms
Excellent update about management of low-grade #myelodysplastic syndrome #MDS at #EHA2023 @EHA_Hematology by Valeria Santini, @Gotzekatharina, @Ramikomrokji and Matteo Della Porta! (@ManelEsteller)
11 months ago
11ms
Highlights Of ASCO: Myelodysplastic Syndromes (MDS) by Dr. @LFletcherMD15 of @WVCancer https://t.co/6yMjQfE8Qw #ASCO23 (@BTFCancerNews)
11 months ago
11ms
Caveat also these trials address transfusion dependent anemia. For symptomatic, but non transfused anemia, e.g. older LE-MDS patient with Hg hovering in the 9 range, many are treated, and think ESA still appropriate (@sameem_abedin)
11 months ago
Clinical
11ms
MyeloDysplastic neoplasmS (MDS) (@henryhmo)
11 months ago
11ms
That’s why I support the new @WHO terminology Myelodysplastic Neoplasms (though prefer the acronym MDS). #ASCO2023 #MDSsm (@TaylorJ_MD)
11 months ago
11ms
Should we start using the term ‘myelodysplastic neoplasms’? (@diegoah66)
11 months ago
11ms
CONGRESS | #ASCO23 | @RoloffGreg @uchicagoleuk presented a phase I study of selumetinib plus azacitidine in pts with high-risk chronic myeloid neoplasms. Eligibility: pts with higher risk MDS, MDS/MPNs, and myelofibrosis. Planned enrolment ~18 participants #MDSsm #medicalcongress (@MDS_Hub)
11 months ago
Clinical • P1 data
|
Koselugo (selumetinib) • azacitidine
11ms
Then maybe Myelodysplatic neoplasm? (@alipath)
11 months ago
11ms
Imetelstat Displays Significant Efficacy in R/R Myelodysplastic Syndrome https://t.co/v6kR8uKMsx via @targetedonc (@Dr_AmerZeidan)
11 months ago
Clinical
|
imetelstat (GRN163L)
11ms
Jordanians 🇯🇴 Against Myelodysplastic Syndrome/Neoplasm @Ramikomrokji @madanatyazan #MDSsm @ASCO #ASCO2023 #ASCO23 (@Dr_AmerZeidan)
11 months ago
11ms
Today’s ASCO Daily News also features @Anand_88_Patel who is a discussant in a session about results of the ph3 COMMANDS trial that support new standard of care tx for myelodysplastic syndromes #ASCO23 (@UCCancerCenter)
11 months ago
11ms
The #ASCO23 session on hematologic malignancies - leukemia, myelodysplastic syndromes, and allotransplant has kicked off with a presentation by @drclaireroddie of @ucl on top line results of the FELIX study, which evaluated obecabtagene autoleucel in relapsed/refractory B-ALL. (@Blood_Cancers)
11 months ago
obecabtagene autoleucel (AUTO1)
11ms
.@Dr_AmerZeidan shared that Imetelstat helped 1/3 of patients with lower-risk myelodysplastic syndromes achieve complete transfusion independence. #ASCO23 #MDSsm #IMerge @ASCO @YaleHematology @SmilowCancer @YaleMed @YNHH @OncoAlert https://t.co/yWm7YLCcDi (@YaleCancer)
11 months ago
Clinical
|
imetelstat (GRN163L)
11ms
Happening Now @ASCO #ASCO23 @RoloffGreg is presenting in an Oral Abstract Session, Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant. @UCCancerCenter @UChicagoMed @UChicagoHemOnc (@UCCancerCenter)
11 months ago
11ms
Results of the COMMANDS trial just presented at #ASCO23: Luspatercept poised to become a new first-line SOC for transfusion-dependent, lower-risk myelodysplastic syndromes: https://t.co/njoMVcJmEf @garciamanero @Anand_88_Patel @MDAndersonNews #ASCODailyNews #HemeOnc (@ASCO)
11 months ago
Clinical
|
Reblozyl (luspatercept-aamt)
11ms
.@Dr_AmerZeidan will share promising results from the phase III IMerge trial #ASCO23. The therapy will have a substantial impact and give hope to patients with Myelodysplastic Syndromes #MDS. @OncoAlert @YaleHematology @SmilowCancer @YaleMed @YNHH @ASCO https://t.co/mNXMu20B70 (@YaleCancer)
11 months ago
Clinical
11ms
🔔 #ESHMDS2024 SAVE THE DATE: April 12-14, 2024 REGISTRATION IS OPEN ➡ https://t.co/srVk8TI3Y1 Join us in Budapest, Hungary 🇭🇺 9th Translational Research Conference: MYELODYSPLASTIC SYNDROMES Chairs: @FenauxP, @GoetzeKatharina, @MikkaelSekeres #ESHCONFERENCES #HAEMATOLOGY #MDSsm (@ESHaematology)
11 months ago
11ms
Connect® MDS/AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry [Dec 12, 2013 - study start date] https://t.co/iJPIrChc7v #NCT01688011 #MDSsm #AMLsm #leusm #oncopath #camoldx #PrecisionMedicine @bmsnews (@mtmdphd)
11 months ago
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login